Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 05 December 2016 - On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 3 February 2016.
Under the programme initiated 28 October 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 4.5 billion in the period from 28 October 2016 to 31 January 2017.
Since the announcement as of 28 November 2016, the following transactions have been made under the programme:
| Number of B shares |
Average purchase price |
Transaction value, DKK |
|
| Accumulated, last announcement | 6,802,101 | 1,572,674,476 | |
| 28 November 2016 | 322,500 | 229.10 | 73,885,621 |
| 29 November 2016 | 326,061 | 230.45 | 75,140,977 |
| 30 November 2016 | 280,000 | 236.37 | 66,184,174 |
| 1 December 2016 | 338,491 | 237.02 | 80,228,600 |
| 2 December 2016 | 305,000 | 236.19 | 72,036,725 |
| Accumulated under the programme | 8,374,153 | 1,940,150,571 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 41,473,135 B shares of DKK 0.20, corresponding to 1.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 3 February 2016. As of 2 December 2016, Novo Nordisk has repurchased a total of 39,549,490 B shares equal to a transaction value of DKK 12,439,909,017.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | [email protected] |
| Ken Inchausti (US) | +1 609 786 8316 | [email protected] |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | [email protected] |
| Melanie Raouzeos | +45 3075 3479 | [email protected] |
| Hanna Ögren | +45 3075 8519 | [email protected] |
| Anders Mikkelsen | +45 3079 4461 | [email protected] |
| Kasper Veje (US) | +1 609 235 8567 | [email protected] |
Company announcement No 85 / 2016
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
